From 2012, our research team led by Professor Yeong-Shiau Pu and Dr. Chung-Hsin Chen proved that aristolochic acid (AA) was a main carcinogen of upper urinary tract urothelial carcinoma (UTUC) in Taiwan. The results of this study have been published in PNAS on May 22, 2012. We then focused on the carcinogenesis of AA and identified single base substitution frequency caused by AA was 10 times of that by other carcinogens, suggesting AA was a very potent carcinogen. In 2016, we reported the identification of TP53 mutation pattern as a part of personalized medicine for UTUC patients. The results of this study have been published in Oncotarget on June 7, 2016. Besides, we proved renal cell carcinoma was also affected by AA in Taiwan. The results of this study have been published in Cancer Epidemiol Biomarkers Prev. on December 25, 2016.
Professor Ho-Hsiung Lin of the Department of Obstetrics and Gynecology of National Taiwan University Hospital and Dr. Sheng-Mou Hsiao of the Department of Obstetrics and Gynecology of Far Eastern Memorial Hospital jointly published a study about re-treatment after discontinuation of antimuscarinic therapy or continuous antimuscarinic therapy for women with overactive bladder syndrome. The study found that frequent nocturia episodes, which is a suboptimal response, and small bladder capacity may predict persistent antimuscarinic therapy or re-treatment after solifenacin treatment of women with persistent or recurrent factors. The results of this study have been published in the online version of the journal Menopause on September 21, 2016.